Wegovy, a weight loss drug which reduces cardiovascular risks in obese individuals, launched in India on June 24. Experts ...

CHICAGO -- Semaglutide (Ozempic) reduced glucose levels and weight among patients with type 1 diabetes and obesity, a ...

Danish drugmaker Novo Nordisk on Tuesday launched its blockbuster weight-loss drug Wegovy as a once-a-week injection in India ...

The drug works by acting on key areas of the brain involved in appetite regulation and food intake thereby reducing hunger, ...

Novo Nordisk launches Wegovy, its anti-obesity drug, in India. Targeting a large obese population, Wegovy aims to improve ...

Novo Nordisk decodes India’s obesity drug market with Wegovy positioned as once-a-week novel weight management medication: ...

We wanted to price it in India in a way which is comparable to the therapies that are available,' said Vikrant Shrotriya, ...

Wegovy is the first drug in India approved for both weight management and risk reduction of major adverse cardiovascular events in individuals with established heart disease.

Novo Nordisk is banking on its pen-filled device and insulin leadership in India to gain a strong market share despite ...

Pricing Details. The 0.25 mg, 0.5 mg and 1 mg dosage of Novo Nordisk's Wegovy will cost Rs 17,345 for a month. A higher dose form of 1.75 mg will cost Rs 24,280 a month, while 2.4 mg dose will be ...

Mumbai: Novo Nordisk, a global healthcare company headquartered in Denmark, has announced the launch of Wegovy (injectable ...